Recent advances in the development of Mcl-1 inhibitors for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The Bcl-2 protein family regulates mitochondrial apoptosis, crucial in cancer development and therapy resistance.
• Dysregulation of this pathway is a hallmark of many cancers.
• Selective inhibition of pro-survival Bcl-2 proteins is a viable anti-cancer strategy.

Purpose of the Study:

• To review recent advancements in the discovery and development of selective Mcl-1 inhibitors.
• To highlight Mcl-1 inhibitors currently in clinical evaluation for cancer treatment.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of drug discovery efforts targeting Mcl-1.
• Evaluation of clinical trial progress for Mcl-1 inhibitors.

Main Results:

• The success of venetoclax (a Bcl-2 inhibitor) validates targeting other pro-survival Bcl-2 family members.
• Significant progress has been made in developing selective Mcl-1 inhibitors.
• Several Mcl-1 inhibitors are now in clinical trials for various cancers.

Conclusions:

• Selective Mcl-1 inhibition is a promising therapeutic strategy for cancer.
• Ongoing clinical trials will determine the efficacy and safety of Mcl-1 inhibitors in cancer patients.